Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 273473
United States Patent No. 5,057,411 – Type-specific papillomavirus DNA sequences and peptides
IPSCIO Record ID: 336296
Antigen shall mean (i) HPV antigens and/or (ii) HPV proteins and/or (iii) other physical forms based on such antigens, such as peptides and/or nucleic acid(s) (DNA, RNA) delivered in any form including recombinant vectors.
Vaccine Product shall mean an HPV Vaccine (x)covered in whole or in part by a Licensor Patent or an Licensee Patent which covers Licensee Special Technology and/or (y) which incorporates or is derived from the use of Licensor Technology and/or Licensee Special Technology.
Licensor Patents shall mean
5,298,418 – Cell line isolated from larval midgut tissue of Trichoplusia ni
5,300,435 – Trichoplusia ni cell line which supports replication of baculoviruses
5,437,951 – Self-assembling recombinant papillomavirus capsid proteins
Licensor Technology shall mean information, know-how and materials, including, but not limited to, pharmaceutical, chemical and biological products, technical and non-technical data and information (i) owned by Licensor and/or to which Licensor has a transferable interest on the Effective Date and/or at any time during the term of this Agreement and (ii) which relate to the field of L1 based HPV Vaccines and/or which arise from the Research Program, and in each case which are necessary or useful for the development, manufacture, use or sale of an HPV Vaccine.
Human papillomavirus (HPV) is the most common sexually transmitted infection (STI).
Many people with HPV don't develop any symptoms but can still infect others through sexual contact. Symptoms may include warts on the genitals or surrounding skin.
There's no cure for the virus and warts may go away on their own. Treatment focuses on removing the warts. A vaccine that prevents the HPV strains most likely to cause genital warts and cervical cancer is recommended for boys and girls.
IPSCIO Record ID: 273272
US patent No. 5,981,173 – Genital human papillomavirus type 68a (HPV-68a), related to the potentially oncogenic HPV-39
HPV means Human Papillomavirus. It's the most common sexually transmitted infection. HPV is usually harmless and goes away by itself, but some types can lead to cancer or genital warts.
Biological Material means biological material accession No. I-1540 of the cloned genome of the Human Papillomavirus type 68 (HPV68).
Licensed Product means HPV Hybrid Capture(R) II (HPV HCII) and/or any other product using the Licensed Patent and/or the Biological Material or fragments thereof, or derived biological material from Biological Material or fragments thereof, or a synthetic molecule corresponding to said Biological Material or to derived Biological Material or to fragments of both thereof.
IPSCIO Record ID: 336295
Licensee, at Universitys request, shall grant to a third party a royalty bearing, sublicense under Patent Rights in the field defined by Licensee and the third party. Licensee shall be required to grant only one sublicense under this Agreement.
Inventions shall mean new and useful improvements in the construction of Papillomavius hybrid particles conceived and reduced to practice by all employees of University, and disclosed to University in University Invention Disclosure dated September 28, 1994, and December 16, 1996, and as amended from time to time.
IPSCIO Record ID: 274922
Licensor hereby grants non-exclusive licenses (other than the Co-exclusive License for Therapeutic Immunization for HPV Antigens granted in this Agreement C below) in accordance with the terms stated herein.
In consideration of the obligations assumed by Licensee hereunder, Licensor hereby grants to Licensee and to any affiliates of Licensee the following licenses without the right to sublicense as set forth in this paragraph under technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the territory and in the field all products and/or compinations, subject to the following
(A1) For prophylactic immunization within the field, Licensor grants a non-exclusive license for the following licensed antigens (including combinations thereof) and no other antigens.
Steptococcus pneumonia Antigens
(A2) For prophylactic immunization within the field, Licensor grants to Licensee a non-exclusive license for the following licensed antigens and no other antigens.
(B) For therapeutic immunization within the field, Licensor grants Licensee a non-exclusive license for the following licensed antigens (including combinations thereof) and no other antigens.
(C) For therapeutic immunization within the field, licensor grants Licensee a co-exclusive license for the following licensed antigens (including combinations thereof) and no other antigens.
The regulatory and development milestone payments and the patent royalties for each Licensed Antigen in the non-exclusive licenses granted in (A1) and (B) shall be reduced by a certain percent.
HBV – hepatitis B virus
HPV – human papillomavirus
HIV – human immunodeficiency virus
IPSCIO Record ID: 279370
The exclusivity of the foregoing license shall be subject to the retained right of Licensors and their respective Affiliates to practice the Licensor Technology for the purpose of conducting development, manufacture and commercialization of Target Products in the Territory to the extent expressly contemplated by this Agreement.
Licensor Technology shall mean the Licensor Know-How and the Licensor Patent Rights..
Licensor Patent Rights shall mean all Patents that Licensor Controls as of the Execution Date or during the Term, including, without limitation, Patents that claim Licensor Inventions and/or Joint Inventions, which, in the absence of the license granted to Licensee under this Agreement, would be infringed by the making, using, selling, offer for sale or importation of Target Products in the Territory. The Agreement lists all Licensor Patent Rights existing as of the Execution Date (Base Patents).
US Patent #6,338,952 – Stress proteins and uses therefor
US Patent #6,335,183 – Stress proteins and uses therefor
IPSCIO Record ID: 291200
With this agreement the University grants Licensee the exclusive rights to conduct various technical, pre-clinical, marketing, patent, and other studies on products in the field of use during a six (6) month period commencing on the effective date of this Agreement.
The University grants to Licensee
— the exclusive worldwide license in the field of use to use the patent to manufacture and sell the product; and
— the right to grant sublicenses to any patent licensed exclusively, provided that any sublicensee agrees to be bound by the terms and conditions of this Agreement.
CoFactor (5,10 methylenetetrahydrofolate) is a patented new drug which greatly improves the performance of 5-FU (5-Fluorouracil) and other fluoropyrimidines commonly used in cancer chemotherapy.
Selone(TM), for Anticancer, is an alkylating agent for drug-resistant cancers. Selone is the Licensees leading compound in a new class of compounds which are potential new cancer drugs for drug resistant cancer, discovered through the University research focused on the use of the element selenium, an anti-oxidant. We are the exclusive licensee of a patent from the University, which encompasses the use of Selone and other oxygen-carbon-selenium compounds as anticancer agents, as well as the method for their synthesis.